Friday, February 9, 2018
News Recap:
Epidemiology:
CTAC Launches Campaign to End Hepatitis C in Canada. The Canadian Treatment Action Council (CTAC) has published a white paper entitled, "The time has come to eliminate hepatitis C in Canada," which summarizes the increasing gaps in Canada's response to the hepatitis C epidemic and identifies seven calls-to-action.
#EASLmono: Expanding the conversation on hepatitis elimination. The recent European...
Elimination of infection in next 10 years possible through concerted action by policymakers and community leaders.
TORONTO, Feb. 6, 2018 /CNW/ - The Canadian Treatment Action Council (CTAC) has published a white paper entitled, "The time has come to eliminate hepatitis C in Canada," which summarizes the increasing gaps in Canada's response to the hepatitis C epidemic and identifies seven calls-to-action. CTAC is once again demonstrating its commitment to
Friday, November 4, 2017
News Recap:
Access to Treatment
Hepatitis C could be eliminated in Canada, but drug prices, screening barriers stand in the way – Most of the 70 million patients infected with hepatitis C worldwide could be cured for $50 US each Many countries — including Canada — have committed to a global goal of eliminating hepatitis C by 2030. But new data released at the summit in Brazil shows that only nine countries are on track to me...
Most of the 70 million patients infected with hepatitis C worldwide could be cured for $50 US each
Many countries — including Canada — have committed to a global goal of eliminating hepatitis C by 2030. But new data released at the summit in Brazil shows that only nine countries are on track to meet that objective — and Canada is not among them.
Dr. Jordan Feld, a hepatologist at the Toronto Centre for Liver Disease at the University Health Network, sa
Friday, April 7, 2017
News Recap
Canada
Effective April 2017, Alberta Health has expanded access to treatments for hepatitis C in line with what the provinces of British Columbia, Ontario, Saskatchewan, and Québec have just done (Alberta expands drug coverage for hepatitis C patients). As Dr. Shafran, who is clearly worried about continued restrictions, says, “The funders have now opened the doors to let us treat people with mild liver disease … if ...
Decision enables price reductions and scale-up of treatment that leads to cure in 95% of cases
Rio de Janeiro, 31 March, 2017 – Treatment for hepatitis C using the key drug sofosbuvir could be vastly scaled up in Brazil after the decision by the National Agency of Health Surveillance (Anvisa) to reject a key patent application on the drug marketed by pharmaceutical corporation Gilead. The decision could pave the way to enable generic competition in Brazil
HepCBC is seeking individual patient input for our submission to the federal government for an INTERFERON-FREE, ONE PILL/DAY drug combo, shown to be effective for genotypes 1, 3, 4, and 6, Merck Pharmaceutical's elbasvir + grazoprevir (± ribavirin). The treatment's success (96% - 100% SVR12) has been confirmed in trials including people considered 'hard to treat' including those who had failed previous treatment (including simeprevir, boceprevir, and telap
On Monday, September 28, 2015, HepCBC sent a letter (text below) out to all the Provincial Health Ministers except Quebec's, telling them why it is important to patients that they make a decision soon about whether to cover a new hepatic encephalopathy drug, rifaximin. For reference you can read:
HepCBC's Patient Group report to the federal government (CADTH) HERE (includes Jan. 12, 2015 revision added on request of CADTH)
HepCBC's Patient Group re
Message from Organizers of World Hepatitis Summit 2015 in Glasgow, Scotland Sept. 2-4, 2015:
"On behalf of the World Hepatitis Summit partner organisations, we, the Summit Organising Committee, would like to thank you for your attendance and important role at the Summit.
The Summit had over 600 delegates in attendance through the week representing over 90 countries – it truly was a global event. The feedback so far has been very positive and we reali
We are asking for patients to give us input about a new treatment for genotype 4 patients. Are you curious how we use this data? Want to see what HepCBC tells BC Pharmacare, or the federal drug review agencies about patients' opinions of new hepatitis C treatments?
Exactly what did HepCBC tell them about Daklinza (daclatasvir), Holkira Pak (ombitasvir, paritaprevir, ritonavir, and dasabuvir), Harvoni (sofosbuvir+ledipasvir), Sovaldi (sofusbovir), Sunpr...
